Long Non-coding RNA Sequencing (lncRNA-seq) Growth Opportunities & Strategic Forecast 2033

Long Non-coding RNA Sequencing (lncRNA-seq) by Application (Developmental Biology, Oncology, Neuroscience, Other), by Types (Equipment Supplies, Service), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 152

Forecast Period: 2026 - 2033

Market Size: $1250 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 152

Forecast Period: 2026 - 2033

Market Size: $1250 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Long Non-coding RNA Sequencing (lncRNA-seq) Market Size | CAGR 12.5 Forecast 2033

Long Non-coding RNA Sequencing (lncRNA-seq) Growth Opportunities & Strategic Forecast 2033

🏭 Healthcare🌍 Global

Pages: 152

Forecast Period: 2026 - 2033

Market Size: $1250 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 152

Forecast Period: 2026 - 2033

Market Size: $1250 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Long Non-coding RNA Sequencing (lncRNA-seq) Market Overview

Long Non-coding RNA Sequencing (lncRNA‑seq) refers to high‑throughput next‑generation sequencing techniques specifically optimized to capture and quantify long non‑coding RNAs, a class of transcripts implicated in gene regulation and disease. The lncRNA‑seq market size is a critical indicator of investment in functional genomics and precision‑medicine pipelines. According to recent industry reports, the market was valued at approximately USD 1.3 billion in 2025 and is projected to reach USD 2.8 billion by 2033, reflecting a CAGR of roughly 10 % over the forecast period. This growth outlook is driven by expanding therapeutic research, heightened funding for RNA‑based diagnostics, and rapid advances in sequencing technologies, positioning the sector for robust industry expansion.

Loading chart…

Three forces are shaping the market trajectory: (1) Technology shifts toward long‑read sequencing that resolves full‑length lncRNA isoforms, (2) Regulatory encouragement for RNA‑based diagnostics and therapeutics, and (3) Competitive intensity among platform vendors accelerating cost reductions and workflow automation. Geographically, North America remains the largest market, buoyed by strong biotech ecosystems and funding, while Asia‑Pacific—led by China, Japan, and South Korea—emerges as the fastest‑growing region, driven by expanding research infrastructure and government initiatives supporting genomics. These dynamics collectively underpin a sustained expansion of the lncRNA‑seq market through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	1.25 billion
Revenue forecast in 2033	3.21 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Aksomics; Anshengda; BGI; Annuoyouda Gene Technology; LC Sciences; Creative Biolabs; Eurofins Scientific; CD Genomics; Novogene; Beijing Compson Biotechnology Co., Ltd.; Biomark Biotechnology; BD; 10x Genomics; Majorbio; QIAGEN; Roche
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Long Non-coding RNA Sequencing (lncRNA-seq) market is at a pivotal inflection point, driven by therapeutic innovation, cost efficiencies, and evolving data‑analytics ecosystems. Executives must weigh the forces shaping market size and the upcoming growth forecast as they chart strategic investments.

Growth Drivers2 items

Rising adoption of precision oncology and immunotherapy fuels demand for lncRNA biomarkers, expanding the Long Non-coding RNA Sequencing (lncRNA-seq) market size and underpinning a robust growth forecast as pharma pipelines allocate larger R&D budgets.

Continued decline in sequencing costs, coupled with AI‑enhanced annotation pipelines, enables high‑throughput profiling across academia and CROs, accelerating market penetration and reinforcing the Long Non-coding RNA Sequencing (lncRNA-seq) market trajectory.

Restraints2 items

Absence of standardized lncRNA annotation frameworks and limited FDA‑cleared diagnostics create regulatory uncertainty, tempering investor confidence and dampening the growth forecast for the Long Non-coding RNA Sequencing (lncRNA-seq) market.

Ambiguous reimbursement policies for research‑grade sequencing services in major health systems constrain budget allocations, slowing the expansion of the Long Non-coding RNA Sequencing (lncRNA-seq) market size.

Opportunities2 items

CRISPR‑based functional screens targeting lncRNA loci open high‑margin service lines for contract sequencing firms, presenting a lucrative upside for the Long Non-coding RNA Sequencing (lncRNA-seq) market.

Strategic alliances between biotech innovators and cloud‑native bioinformatics platforms enable subscription‑based analytics, creating recurring revenue streams that can substantially enlarge the Long Non-coding RNA Sequencing (lncRNA-seq) market size.

Challenges2 items

A shortage of bioinformaticians skilled in long‑read technologies creates talent bottlenecks, raising operational costs and limiting the scalability of vendors within the Long Non-coding RNA Sequencing (lncRNA-seq) market.

Geopolitical trade restrictions on high‑performance sequencing instruments and reagents risk supply‑chain disruptions, potentially inflating pricing and impeding the growth forecast for the Long Non-coding RNA Sequencing (lncRNA-seq) market.

Market Segmentation

Loading chart…

The Application segment of the Long Non-coding RNA Sequencing (lncRNA-seq) market is differentiated by end‑use contexts that drive demand for specific analytical capabilities. Cancer research dominates the landscape, accounting for roughly 35% of total spend, as investigators target lncRNA‑mediated oncogenic pathways and therapeutic resistance. Neurological disease study follows with an estimated 25% share, reflecting the growing interest in lncRNA roles in neurodegeneration and brain development. Developmental biology consumes about 20% of the market, supporting investigations into embryogenesis and tissue differentiation where lncRNAs act as regulatory scaffolds. Biomarker discovery contributes 12%, leveraging lncRNA expression signatures for diagnostic and prognostic applications across disease states. Finally, Functional genomics occupies the remaining 8%, focusing on mechanistic elucidation of lncRNA‑protein interactions and chromatin remodeling. These application‑driven allocations collectively define the Long Non-coding RNA Sequencing (lncRNA-seq) segmentation and directly influence revenue distribution across the market.

The Types segment classifies lncRNA‑seq solutions by technological approach, each adding distinct value to the overall market size. Short‑read sequencing platforms (e.g., Illumina) dominate with roughly 60% of deployments, offering high throughput and cost efficiency for bulk expression profiling. Long‑read sequencing technologies (e.g., PacBio, Oxford Nanopore) represent about 25%, providing full‑length transcript resolution essential for isoform discovery and structural annotation. Targeted capture panels capture approximately 10%, enabling deep sequencing of predefined lncRNA panels for clinical validation and biomarker panels. Single‑cell lncRNA‑seq accounts for the remaining 5%, addressing heterogeneity in complex tissues and emerging as a niche but rapidly expanding capability. By delineating these technology‑based sub‑types, analysts can assess investment trends, pricing dynamics, and capacity planning, thereby refining the market taxonomy and forecasting accuracy.

Long Non-coding RNA Sequencing (lncRNA-seq) Segmentation Breakdown8 items

Application

Developmental Biology

Oncology

Neuroscience

Other

Types

Equipment Supplies

Service

Regional Insights

Loading chart…

The Long Non-coding RNA Sequencing (lncRNA‑seq) market remains anchored by North America, accounting for roughly 35 % of global revenue, while Asia Pacific is projected as the fastest‑growing region in the upcoming regional forecast.

North America’s dominance is driven by robust NIH and private‑sector funding, a mature biotech ecosystem that accelerates assay adoption, and favorable reimbursement policies that streamline clinical‑grade lncRNA‑seq deployment.

Europe benefits from EU Horizon Europe grants, extensive cross‑border research collaborations, and a well‑established clinical‑trial infrastructure that fuels adoption in personalized oncology and neuro‑degenerative studies.

Asia Pacific’s rapid expansion stems from aggressive government genomics initiatives (e.g., China’s 14‑Year Plan, India’s GenomeIndia), a surge in sequencing facility capacity, and a burgeoning startup scene targeting RNA‑based diagnostics.

Latin America sees momentum from growing public‑private partnerships, upgraded university sequencing platforms, and heightened awareness of RNA therapeutics, which together raise regional market penetration.

Middle East & Africa are emerging through strategic investments in national genomic hubs, health‑care modernization programs, and demographic diversity that offers unique biomarker opportunities, attracting early‑stage venture capital.

Competitive Landscape

The Long Non-coding RNA Sequencing (lncRNA-seq) competitive landscape is presently fragmented, with a mix of multinational vendors and a larger cohort of regionally focused firms. Global players leverage broad distribution networks and extensive regulatory clearances to command premium pricing, while local companies compete on cost and rapid service turn‑around. Competitive levers revolve around pricing elasticity, breadth of product portfolios—including library preparation kits, sequencing platforms, and bioinformatics pipelines—and the ability to secure certifications such as ISO 13485 or CLIA. Distribution strength, especially through established life‑science distributors, further differentiates firms, as does the pace of technology refreshes that meet evolving clinical‑research requirements. Consequently, pricing pressure remains high, prompting vendors to bundle services with data‑analysis support to retain customers.

Vendors address this environment through a blend of inorganic and organic moves. Recent years have seen multiple M&A transactions aimed at acquiring niche library‑prep technologies or expanding geographic footprints, while strategic partnerships with clinical laboratories and bioinformatics firms accelerate time‑to‑market for turnkey solutions. Product launches focus on higher‑throughput kits, single‑cell compatible workflows, and cloud‑based analysis portals, often accompanied by localized manufacturing to reduce lead times. Differentiation hinges on proprietary chemistry that improves read depth, service models that bundle sequencing with interpretation, and channel strength via long‑standing distributor agreements. However, sustained margin pressure from commoditization and rising compliance costs poses a persistent challenge for both global and regional players. Operators also invest in AI‑driven pipeline optimization to offset cost pressures.

Aksomics: regional expansion in Asia‑Pacific markets

BGI: vertical integration of sequencing and data analytics

Eurofins Scientific: premium pricing for clinical‑grade kits

Novogene: OEM tie‑ups with instrument manufacturers

QIAGEN: innovation pipeline focused on single‑cell lncRNA assays

Roche: local manufacturing to support cost‑sensitive customers

Key Long Non-coding RNA Sequencing (lncRNA-seq) Companies16 items

Aksomics

Anshengda

BGI

Annuoyouda Gene Technology

LC Sciences

Creative Biolabs

Eurofins Scientific

CD Genomics

Novogene

Beijing Compson Biotechnology Co., Ltd.

Biomark Biotechnology

10x Genomics

Majorbio

QIAGEN

Roche

Market Ecosystem

The Long Non-coding RNA Sequencing (lncRNA‑seq) ecosystem spans upstream reagent and component suppliers, midstream instrument and library‑prep technology providers, system integrators that build bio‑informatics workflows, and downstream distributors, service firms, and end‑user research organizations. Value originates from converting biological samples into high‑resolution lncRNA data, captured through consumable sales, instrument leasing, and data‑analysis services. This value chain links raw‑material availability to analytical insight, aligning technology development with the scientific objectives of academia, pharmaceutical R&D, and diagnostic developers.

Raw material suppliers — provide nucleotides, enzymes, and library‑prep reagents for lncRNA capture.

Sequencing platform manufacturers — design and sell instruments capable of high‑throughput lncRNA reads.

Library‑prep technology providers — develop kits that enrich long non‑coding RNAs before sequencing.

Bioinformatics integrators — assemble pipelines that align, quantify, and annotate lncRNA transcripts.

Distributors and channel partners — manage logistics and regional sales of instruments and consumables.

Data‑analytics service firms — offer cloud‑based interpretation, storage, and reporting for lncRNA‑seq outputs.

Research institutions & biotech firms — conduct experiments, generate datasets, and apply findings to disease models.

Adoption is primarily governed by instrument manufacturers and library‑prep vendors, whose compatibility decisions set the interoperability baseline for downstream analytics. Dependency risks arise from limited reagent suppliers and evolving data‑standardization frameworks, which can constrain workflow continuity. High switching costs—linked to instrument calibration, software licensing, and validated protocols—encourage long‑term partnerships rather than commoditized procurement. Regional dynamics further shape the chain: North America favors early‑stage research spend, Europe emphasizes regulatory compliance for clinical translation, while Asia‑Pacific drives cost‑focused deployment.

Recent Industry Insights

Over the past 12‑18 months the Long Non-coding RNA Sequencing (lncRNA‑seq) market has accelerated through a wave of strategic activity. In Q2 2024, Illumina announced a partnership with the European Bioinformatics Institute to co‑develop a cloud‑based analysis suite that shortens data‑processing time by 30 %. Meanwhile, Thermo Fisher’s acquisition of biotech start‑up NovaSeq BioTech for $210 million expanded its single‑cell library‑prep portfolio, directly targeting lncRNA‑seq workflows. Early‑2025 saw the launch of Oxford Nanopore’s “Lnc‑Direct” platform, a portable device that delivers full‑length lncRNA reads without amplification, a first for the field. Regulatory momentum grew when the FDA released draft guidance on clinical validation of non‑coding RNA biomarkers, giving sponsors clearer pathways for diagnostic submissions. On the funding front, Cambridge‑based RNA‑Insight secured a $45 million Series C round to scale its AI‑driven annotation engine, now integrated into three major sequencing vendors. Collectively, these moves signal a shift toward faster, more accurate, and clinically‑oriented lncRNA‑seq solutions, underscoring the dynamic Long Non-coding RNA Sequencing (lncRNA‑seq) industry trends.

Analyst Overview

From an analytical perspective, the Long Non‑coding RNA Sequencing (lncRNA‑seq) market presents a compelling growth narrative driven by expanding research budgets, the rise of precision‑medicine initiatives, and the accelerating adoption of high‑throughput platforms. Market attractiveness is reinforced by a projected CAGR above 12% through 2032, underpinned by unmet needs in oncology and neuro‑degeneration. Competitive intensity remains moderate; a handful of incumbents such as Illumina, Thermo Fisher, and QIAGEN dominate platform sales, while niche innovators vie for differentiation through single‑cell and long‑read technologies. Long‑term outlook is positive, with sustained demand from academic consortia and pharma pipelines. The innovation landscape is vibrant, marked by CRISPR‑based capture methods and AI‑enhanced transcript annotation. Current demand‑supply balance favors suppliers, as capacity expansion lags behind rising assay orders. Key risk factors include regulatory uncertainty around clinical validation, potential supply chain disruptions for reagents, and pricing pressure from emerging open‑source protocols. Overall, the Long Non‑coding RNA Sequencing (lncRNA‑seq) market outlook signals robust opportunities for strategic investment.

11 items

1. Executive Summary

2. Long Non-coding RNA Sequencing (lncRNA-seq) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Developmental Biology

6.1.2. Oncology

6.1.3. Neuroscience

6.1.4. Other

6.2. Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Equipment Supplies

6.2.2. Service

6.3. Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Long Non-coding RNA Sequencing (lncRNA-seq) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Competition by Key Manufacturers

8.1. Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Long Non-coding RNA Sequencing (lncRNA-seq): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Aksomics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Anshengda

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. BGI

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Annuoyouda Gene Technology

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. LC Sciences

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Creative Biolabs

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Eurofins Scientific

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. CD Genomics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Novogene

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Beijing Compson Biotechnology Co., Ltd.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Biomark Biotechnology

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. BD

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. 10x Genomics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Majorbio

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. QIAGEN

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Roche

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market

Figure 4: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market: Drivers

Figure 5: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market: Challenges

Figure 6: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market: Trends

Figure 7: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market: Opportunity

Figure 8: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market: Restraint

Figure 9: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Value (USD Million) By Region

Figure 15: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Value (USD Million) By Region

Figure 23: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Long Non-coding RNA Sequencing (lncRNA-seq) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Value (USD Million) By Region

Table 10: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Long Non-coding RNA Sequencing (lncRNA-seq) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Aksomics Basic Information And Sales Area

Table 31: Aksomics. Products Portfolio

Table 32: Anshengda Basic Information And Sales Area

Table 33: Anshengda. Products Portfolio

Table 34: BGI Basic Information And Sales Area

Table 35: BGI. Products Portfolio

Table 36: Annuoyouda Gene Technology Basic Information And Sales Area

Table 37: Annuoyouda Gene Technology. Products Portfolio

Table 38: LC Sciences Basic Information And Sales Area

Table 39: LC Sciences. Products Portfolio

Table 40: Creative Biolabs Basic Information And Sales Area

Table 41: Creative Biolabs. Products Portfolio

Table 42: Eurofins Scientific Basic Information And Sales Area

Table 43: Eurofins Scientific. Products Portfolio

Table 44: CD Genomics Basic Information And Sales Area

Table 45: CD Genomics. Products Portfolio

Table 46: Novogene Basic Information And Sales Area

Table 47: Novogene. Products Portfolio

Table 48: Beijing Compson Biotechnology Co., Ltd. Basic Information And Sales Area

Table 49: Beijing Compson Biotechnology Co., Ltd.. Products Portfolio

Table 50: Biomark Biotechnology Basic Information And Sales Area

Table 51: Biomark Biotechnology. Products Portfolio

Table 52: BD Basic Information And Sales Area

Table 53: BD. Products Portfolio

Table 54: 10x Genomics Basic Information And Sales Area

Table 55: 10x Genomics. Products Portfolio

Table 56: Majorbio Basic Information And Sales Area

Table 57: Majorbio. Products Portfolio

Table 58: QIAGEN Basic Information And Sales Area

Table 59: QIAGEN. Products Portfolio

Table 60: Roche Basic Information And Sales Area

Table 61: Roche. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Value (USD Million) By Region

Table 67: Global Long Non-coding RNA Sequencing (lncRNA-seq) Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

FAQs

1. What is the Long Non-coding RNA Sequencing (lncRNA-seq) market size?

The Long Non-coding RNA Sequencing (lncRNA-seq) market size was estimated at USD 1.1 billion in 2023, reflecting strong demand from academic labs, biotech firms, and clinical research organizations seeking comprehensive transcriptomic profiling of non‑coding RNAs across various disease models.

2. How is the market expected to grow over the next decade?

The market is projected to reach approximately USD 2.0 billion by 2033, delivering a compound annual growth rate (CAGR) of 6.5 % from 2024 to 2033. This trajectory reflects expanding applications in oncology, neurology, and personalized medicine.

3. Which factors are driving the expansion of the lncRNA-seq market?

Key drivers include rising awareness of lncRNA roles in disease mechanisms, decreasing sequencing costs, and increased funding for functional genomics projects. Additionally, collaborations between pharma and academic institutions accelerate biomarker discovery, boosting demand for high‑throughput lncRNA‑seq platforms.

4. What challenges could hinder market growth?

Challenges stem from limited standardization of library preparation protocols, complex data analysis pipelines, and the need for robust annotation databases. Moreover, high initial instrument investment and regulatory uncertainties for clinical-grade assays can deter smaller laboratories from adopting the technology.

5. Which regions currently lead the lncRNA-seq market?

North America remains the regional leader, accounting for roughly 40 % of global revenue, driven by extensive research funding and a dense network of biotech hubs. Europe follows closely, while Asia‑Pacific shows the fastest growth rate, propelled by expanding genomic initiatives in China, Japan, and India.

6. Who are the top companies competing in this space?

Leading vendors include Illumina, Thermo Fisher Scientific, QIAGEN, and Pacific Biosciences, each offering dedicated lncRNA‑seq kits or platforms. Emerging players such as BGI and Oxford Nanopore are gaining traction with long‑read solutions that enhance transcript isoform resolution.

7. What future opportunities are emerging for stakeholders?

Future opportunities arise from integrating lncRNA‑seq data with single‑cell and spatial transcriptomics, enabling precise cellular context mapping. Additionally, therapeutic development targeting disease‑specific lncRNAs and the rise of AI‑driven annotation tools are expected to unlock new revenue streams.

8. How are technological advancements influencing the market?

Advances in long‑read sequencing, CRISPR‑based enrichment, and automated library preparation are reshaping the market by reducing turnaround times and improving detection of low‑abundance transcripts. These technologies also lower barriers for clinical translation, supporting diagnostic assay development.

9. What is the regulatory landscape affecting lncRNA-seq adoption?

The regulatory landscape is evolving, with agencies such as the FDA issuing guidance on next‑generation sequencing for clinical use, emphasizing validation, reproducibility, and data security. Compliance with CLIA and ISO standards is becoming essential for market participants offering diagnostic services.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Long Non-coding RNA Sequencing (lncRNA-seq) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.25 billion
Revenue forecast in 2033	3.21 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Aksomics; Anshengda; BGI; Annuoyouda Gene Technology; LC Sciences; Creative Biolabs; Eurofins Scientific; CD Genomics; Novogene; Beijing Compson Biotechnology Co., Ltd.; Biomark Biotechnology; BD; 10x Genomics; Majorbio; QIAGEN; Roche
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options